Medivir Investor Relations Material
Latest events
Q4 2023
Medivir
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Medivir
Access all reports
Segment Data
Access more data
Net sales by
Source
Royalty
Expenses by
Financials
Medivir AB researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. It focuses on targeted therapies and vaccines. The company offers Merivo alfa, a product that has completed late stage clinical trials; MIV-711, which has completed phase I/II clinical trials; MIV-102 that has completed phase I/II clinical trial; and other projects in various phases of clinical development. Medivir AB was founded in 1987 and is headquartered in Huddinge, Sweden.
Key slides for Medivir
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇸🇪 Sweden